Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks

Wednesday, 17 July 2019

Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (TSXV: $KHRN.V) (CSE: $ABCS.C) (TSX: $FIRE.TO) (CSE: $CURA.C) (TSXV: $HVT.V) (CSE: $NTAR.C)


Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (TSXV: $KHRN.V) (CSE: $ABCS.C) (TSX: $FIRE.TO) (CSE: $CURA.C) (TSXV: $HVT.V) (CSE: $NTAR.C)



Delta, Kelowna, BC –July 17, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:



Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com “potcasts”, looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few early announcements.

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) announced today that it has received approval from the National Cultivar Registry and the Technical Direction of the ICA for the commercialization of 17 stains of cannabis. The approvals bring the total number of registered strains to 22 and positions the Company to commercialize and distribute CBD cannabis, which is currently being cultivated at Khiron's facility near Ibague, Colombia. This development, which results from a successful ICA operational review, firmly positions the Company to commercialize its medical cannabis product sales in the third quarter of 2019. 

The Company intends to begin commercial production of CBD extract in 2019. This production will be used primarily to produce medicine and sold to patients individually as specifically prepared formulations. This direct to patient distribution method is anticipated to deliver higher margins than producers focused on wholesale export distribution models. Based on independent market research, it is estimated that Colombia has upwards of 6 million potential patients for medical cannabis products (IMS Quintiles). Benefitting from the proprietary independent market research Khiron has commissioned, the Company's medical and scientific teams will utilize state-of-the-art cultivation and extraction processes to produce a portfolio of predefined, precise, and effective formulations to address the unmet medical needs of patients.

In addition to commercializing CBD production, the Company's proprietary psychoactive cannabis varieties ("THC") have now undergone and completed a rigorous regulatory process to receive strain approval from ICA. With these strain approvals, Khiron can now work to obtain approval of the THC strains for commercial quota issuance with the Quota Technical Group. Before commercial quotas can be awarded, the Company must demonstrate an established market demand and distribution method. Based on the potential addressable patient network Khiron has established with medical associations and the ILANS acquisition, the Company believes it has established a leading position in terms of receiving a favorable quota allocation. To date there have been no awards of commercial quotas for THC in Colombia.     

Alvaro Torres, CEO of Khiron Life Sciences, commented, "Khiron has continually focused on expediting our timing to market, while ensuring the highest standards of product quality and consistency. With these approvals secured, Khiron is now poised to introduce its medical cannabis products in Colombia by the third quarter of this year, which once again, demonstrates the Company's in-depth understanding of patient needs, its strategic and evidence-based approach, unparalleled regulatory knowledge, and its leadership role in the Latin American market."

Abacus Health Products, Inc. (CSE: ABCS) (OTCQX: ABAHF) today announced a new retail purchase order by Valu Merchandisers Company for its line of CBDMEDIC™ products.

Valu Merchandisers is a cooperative food distributor serving over 3,800 independently-owned supermarkets in 30 U.S. states and who confirmed an order with Abacus that will see 11 SKUs from the CBDMEDIC™ product line placed in 350 retail stores across six states, with expansion to more than 1,000 locations over the next six months. This new purchase order increases Abacus' total retailer store count to approximately 2,550 locations in 15 states throughout the U.S. The Company remains on track to reach 4,000 retail locations by the end of Q3 2019, as per the guidance previously provided by management.

"Valu Merchandisers is a trusted name in the health and wellness segment and we are delighted that they have chosen to introduce CBDMEDIC™ to their network," said Perry Antelman, CEO of Abacus.  "This purchase order further illustrates how we continue to execute on our retail growth strategy and add retail chains with significant presence across the United States."

The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) today announced that it has entered into a definitive agreement under which Supreme Cannabis will acquire all of the issued and outstanding shares of privately-held Truverra Inc., to be effected by way of a three-cornered amalgamation between Truverra, Supreme Cannabis and a wholly-owned subsidiary of Supreme Cannabis. The Transaction is valued at 14.7 million common shares of Supreme Cannabis, giving the Transaction an approximate dollar value of $20,000,000 as of the Company's closing price on July 16, 2019.

Located in Toronto, Truverra is a private cannabis company, serving the Canadian and international cannabis markets through its wholly-owned subsidiaries, Canadian Clinical Cannabinoids Inc. and Truverra (Europe) B.V.
         
CCC operates a 5,000 square-foot Health Canada licensed facility in Scarborough, Ontario. Supreme Cannabis intends to repurpose CCC's state-of-the-art facility to produce high-quality cannabis extracts, including concentrates and vaping liquids. In addition to its operations in Canada, Truverra's wholly-owned European subsidiary, Truverra Europe, is located in the Netherlands and sells a broad portfolio of hemp-based CBD products into select European markets.
         
"The recent introduction of Health Canada's amended cannabis regulations creates a distinct opportunity for Supreme Cannabis to establish a leading position in the cannabis extracts markets. With the acquisition of Truverra, we secure a Toronto-based facility equipped to extract our high-quality inputs for concentrates and vaping liquids in the near-term," said Navdeep Dhaliwal, CEO of Supreme Cannabis. "Truverra's operations also provide an additional entry point into Europe's CBD wellness market, where Truverra Europe has successfully launched multiple CBD products in various jurisdictions. Truverra's Canadian and European operations are managed by a senior leadership team with a wealth of experience manufacturing and launching products in highly-regulated industries such as life sciences and pharmaceuticals."

"The Supreme Cannabis Company has a strong track record for executional excellence, with their support and robust corporate services we look forward to strengthening our operations in Canada and globally," said Jeff Adams, CEO of Truverra. "In the near term, we will continue to build Truverra's CBD offering in Europe and position the brand to serve international medical markets."

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) today announced that it has signed a definitive agreement to acquire GR Companies, Inc. ("Grassroots"), the largest private vertically-integrated multi-state operator, in a cash and stock deal valued at approximately $875 million. This transaction solidifies Curaleaf's position as the world's largest cannabis company by revenue and the largest in the U.S. across key operating metrics.

The highly complementary acquisition brings together the largest public and largest private multi-state operators in the U.S. to offer a full range of products to consumers in states across the country. As a market leader throughout the Midwest, Grassroots has a portfolio of 61 dispensary licenses, with 20 operating today, and 17 cultivation and processing licenses that will substantially accelerate Curaleaf's continued expansion across the nation.

Grassroots has a leading presence in large markets in which Curaleaf presently does not operate, including Illinois, which in June became the 11th state to legalize adult-use cannabis, and Pennsylvania, the fifth most populous state in the U.S. The proposed transaction will expand Curaleaf's presence from 12 to 19 states, and the combined company will have 131 dispensary licenses, 68 operational locations, 20 cultivation sites and 26 processing facilities1. With the acquisition, Curaleaf will also add new markets in Arkansas, Michigan, North Dakota, Oklahoma, and Vermont, and build on its existing businesses in Connecticut, Maryland, Nevada and Ohio. Upon completion of the proposed transaction, Curaleaf will be the largest medical and adult-use cannabis company with access to a total population of approximately 177 million people. 

"With the acquisition of Grassroots and the pending acquisition of Select, Curaleaf is the world's largest cannabis company by both revenue and operating presence," said Joseph Lusardi, CEO of Curaleaf. "With a combined 68 open dispensaries, this transaction significantly accelerates our expansion strategy and strengthens our reach across the medical and adult-use markets. In addition, it enhances the depth of our retail and wholesale platform across the country. By leveraging our scale, as well as our market leading capabilities and expertise, we will continue to deliver value for our shareholders."

Mitch Kahn, co-founder and CEO of Grassroots, said, "Today's announcement is a testament to the hard work of the many employees that helped make Grassroots the leading cannabis company in the Midwest. This acquisition will enable us to give our patients and retail partners greater access to products that adhere to the highest standards of quality and reliability, and our employees the opportunity to be part of a best-in-class operator."

Harvest One Cannabis Inc. (TSXV: HVT) (OTCQX: HRVOF) today announced that the Company, through its wholly-owned subsidiary, Satipharm Ltd., has entered into a Supply Agreement with GenCanna Global USA dated June 4, 2019. Under the terms of the Agreement, GenCanna will supply Harvest One with GMP Certified CBD oil and finished products for distribution in regulated markets in the United States, Europe, and around the globe, currently under the Dream Water, Satipharm, and LivRelief™ brands for an initial term of two years. In addition, GenCanna will support the Company in the research, development, and formulation of both existing and new CBD-infused products.

With an industry-leading 38,000+ retail distribution points around the globe (including, Walmart US, CVS, Kroger, Shoppers Drug Mart, Loblaw, Holland & Barrett and Boots), Harvest One is quickly becoming a leading global house of brands in the health, wellness, and self-care sectors, with cannabis, cannabis-infused, and all-natural product offerings. From Satipharm's patented GelPell® CBD capsules, to Dream Water's all natural, single shot sleep products, and the recent addition of LivRelief™, Canada's leading all natural topical pain relief cream, the Agreement with GenCanna ensures the consistent supply of premium quality hemp-derived CBD for infusion of our existing products and further product innovation.
"Working with world-class partners like GenCanna to supply premium quality, traceable, consistent ingredients, all from GMP-certified facilities, is critical to our core strategy at Harvest One to only offer consumers best-in-class premium products, with consistent and predictable effects, in delivery formats they have come to understand and demand" said Grant Froese, Chief Executive Officer of Harvest One. Mr. Froese added, "this Agreement signals the beginning of a global relationship with GenCanna under which we will continue to innovate, infuse our existing portfolio of products, and bring new products to market under our well-recognized and trusted, Satipharm, Dream Water, and LivRelief™ brands".
         
"Our evolving relationship with Harvest One reflects both companies' devotion to consumer product quality" said Steve Bevan, Executive Chair of GenCanna. "Joint research and development have combined to provide excellent CBD product additions to Harvest One's suite of leading-edge brands. We expect that consumers will quickly welcome these products on retail shelves globally" added Steve Bevan.
NexTech AR Solutions (OTCQB: NEXCF) (CSE: NTAR) announced that it has entered into an agreement with Touchstone Home Products to ARitize™ its product line. NexTech AR and Touchstone Home Products, Inc. are launching a 6 product step-off into web-based AR experiences for e-retail, with future plans to fully ARitize the Touchstone Home Products, Inc. line of home furnishings, harnessing the power of conversion-boosting webAR experiences.

Frank Quinlisk, Touchstone Home Products Vice President of Marketing, explains, “Furniture shopping is a very tangible process. With NexTech AR technology, we are able to bring our TV Lift Cabinet and Fireplace showroom experiences to life. Online shoppers can view the TV lift cabinet or Electric Fireplaces from every angle and zoom in to see the quality construction up close. We are pleased to offer this in-depth product view to our customers who aren’t able to visit our showroom in person.”

NexTech’s ARitize™ eCommerce solution is a monthly software as a service (SaaS) software licensing and delivery model in which software is licensed on a subscription basis while being centrally hosted in the cloud. NexTech’s SaaS subscription platform enables companies like Touchstone to transform 2D images into true 3D AR experiences. Utilizing simple embed coding, NexTech’s browser-based technology eliminates the gap online shoppers feel between themselves and the product, allowing them to effectively try or place the product in their home before they buy it.

“I am pleased that we are continuing to execute on our business plan of signing up customers to our SaaS subscription platform for our webAR e-commerce solutions, as every customer we sign up brings us one step closer to profitability,” comments Evan Gappelberg, CEO of NexTech. “Our webAR product images and rotation capabilities are the best on the market and will enable buyers to fully examine and understand the product before they buy, similar to how they would experience in-store shopping. We’re excited to help Touchstone provide its customers with a one-of-a-kind immersive eCommerce experience.”

Gartner recently reported that roughly 100 million consumers will shop in augmented reality online and in-store by 2020.

“Retailers are under increasing pressure to explain the purpose of physical stores, and take control of the fulfillment and return process for cross-channel execution,” said Hanna Karki, principal research analyst at Gartner. “At the same time, consumers are progressively defining the value provided by the experiences they receive from retailers. As a result of these pressures, retailers are turning to AR and VR to offer customers a unified retail experience inside and outside retail stores.”

NexTech is building out its AR and AI eCommerce offerings, which include using AI to create a guided and knowledgeable curator that can be programmed to be used for eCommerce or for education in the medical device market.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   


Subscribe to the new cannabis podcast series:


To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Follow us on Social Media

Contact Investorideas.com
800-665-0411



  


Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directories


No comments:

Post a Comment

Public Support for Legalization Remains Strong, Despite Narrow Shortcomings in Challenging State Elections

Public Support for Legalization Remains Strong, Despite Narrow Shortcomings in Challenging State Elections : Public Support for Legalization...